From the CEO's AGM Presentation (page 6) - Delivery against 2018 Objectives:
_________
DX1 – TNBC brain metastases animal data
Q4 2018
DX1 – Additional solid cancer (TBC) animal data
Q1 2019
DX1 + radiation – brain cancer animal data
Q4 2018/Q1 2019
_________
From the CEO's AGM Presentation (Page 22) - Looking Ahead:
_________
DX1 + radiation – brain cancer animal data
Q4 2018/Q1 2019
DX1 – solid cancer (TBC) animal data
Q1 2019
DX1 + temazolamide – brain cancer animal data
Q1 2019
________
Comment: A couple of differences there. A far cry from the mid year and more straightforward
Aug 2018 - Solid cancer animal data
Oct 2018 - Additional solid cancer animal data
(neither of which materialised).
Also, wonder what happened to the provision of 'more complete pharmacokinetic profiling' (ann of 05-07-2018).
Sometimes silence is not golden. Easy to conclude things are not going exactly to plan.
Ann: Chairman's Address and CEO Presentation to 2018 AGM, page-51
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $43.28K | 6.183M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 237374 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1732079 | 8 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PAB (ASX) Chart |